Aberrant Connection Formation and Glia Involvement in the Progression of Phar-macoresistant Mesial Temporal Lobe Epilepsy
Por:
Vega-García A., Guevara-Guzmán R., García-Gómez O., Feria-Romero I., Fernández-Valverde F., Alonso-Vanegas M., Orozco-Suárez S.
Publicada:
1 ene 2022
Resumen:
Epilepsy is the most common chronic neurological disease, affecting approximately 65 million people worldwide, with mesial temporal lobe epilepsy (mTLE) being the most common type, characterized by the presence of focal seizures that begin in the hippocampus, and subsequently generalize to structures such as the cerebral cortex. It is estimated that approximately 40% of patients with mTLE develop drug resistance (DR), whose pathophysiological mechanisms remain unclear. The neuronal network hypothesis is one attempt to understand the mechanisms underlying resistance to antiepileptic drugs (AEDs), since recurrent seizure activity generates excitotoxic damage and activation of neuronal death and survival pathways that, in turn, promote the formation of aberrant neuronal networks. This review addresses the mechanisms that are activated, perhaps as compensatory mechanisms in response to the neurological damage caused by epileptic seizures, but that affect the formation of aberrant connections that allow the establishment of inappropriate circuits. On the other hand, glia seems to have a relevant role in post-seizure plasticity, thus supporting the hypothesis of the neuronal network in drug-resistant epilepsy, which has been proposed for ELT. © 2022 Bentham Science Publishers.
Filiaciones:
Vega-García A.:
Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Guevara-Guzmán R.:
Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
García-Gómez O.:
Neurological Diseases Medical Research Unit, Specialty Hospital, “Dr. Bernardo Sepúlveda”, National Medical Center “XXI, Century”, Mexican Social Security Institute, IMSS, Mexico City, Mexico
Department of Biochemistry, Biomedi-cine and Molecular Biotechnology, Experimental Chemotherapy Laboratory, National School of Biological Sciences, National Polytechnic Institute, Mexico
Feria-Romero I.:
Neurological Diseases Medical Research Unit, Specialty Hospital, “Dr. Bernardo Sepúlveda”, National Medical Center “XXI, Century”, Mexican Social Security Institute, IMSS, Mexico City, Mexico
Fernández-Valverde F.:
Laboratory of Experimental Pathology, National Institute of Neurology and Neurosurgery, "Manuel Velasco Suárez", Ministry of Health, Mexico City, Mexico
Alonso-Vanegas M.:
International Center for Epilepsy Surgery, HMG Hospital Coyoacan, Mexico City, Mexico
Orozco-Suárez S.:
Neurological Diseases Medical Research Unit, Specialty Hospital, “Dr. Bernardo Sepúlveda”, National Medical Center “XXI, Century”, Mexican Social Security Institute, IMSS, Mexico City, Mexico
|